GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Capex-to-Operating-Income

QNCX (Quince Therapeutics) Capex-to-Operating-Income : 0.00 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Quince Therapeutics's Capital Expenditure for the three months ended in Sep. 2024 was $-0.05 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-8.55 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Quince Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Quince Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Capex-to-Operating-Income Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Quince Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Quince Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Quince Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quince Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Capex-to-Operating-Income falls into.



Quince Therapeutics Capex-to-Operating-Income Calculation

Quince Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.16) / -27.142
=N/A

Quince Therapeutics's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.046) / -8.546
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quince Therapeutics  (NAS:QNCX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Quince Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Quince Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Executives
Dirk Thye director, officer: Chief Executive Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah officer: Chief Business Officer 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Charles S. Ryan officer: President C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer officer: Chief Scientific Officer 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Margaret Mcloughlin director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon officer: Chief Accounting Officer C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell officer: Chief Legal & Adm. Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Philip S Low director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Karen L. Smith officer: Chief Medical Officer C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy director, officer: Chief Scientific Officer C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe officer: Chief Financial Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258